Farastuk Bozorgmehr

7PUBLICATIONS
21CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 19, 2026
Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.

|May 31, 2026
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.

|May 19, 2026
Differential effects of prior versus concomitant Steroid and Antibiotic Treatment on Immunotherapy Efficacy - A Pooled Analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC Trials of the German AIO Study Group.

|Mar 27, 2025
NeoTRACK trial: Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy - dissection of IO- efficacy in NSCLC by longitudinal tracKing - protocol of a non-randomised, open-label, single-arm, phase II study.

Romina M Roesch, Johannes Schnorbach, Laura V Klotz

|Sep 24, 2022
Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease - a randomized, open-label, multicenter phase II trial.

Farastuk Bozorgmehr, Petros Christopoulos, Inn Chung

|Aug 27, 2020
Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial.

Farastuk Bozorgmehr, Inn Chung, Petros Christopoulos

Pageof 2

Frequent Collaborators

2 joint publications

Meike Hutt

2 joint publications

Simon Laban

2 joint publications

Moritz Kleemiss

2 joint publications

Manuel Ruh